Literature DB >> 31728673

Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study.

Yael Borovitz1, Hadas Alfandary1,2, Orly Haskin1, Shely Levi1,2, Shulamit Kaz1, Miriam Davidovits1,2, Amit Dagan3,4.   

Abstract

Relapses of steroid-sensitive nephrotic syndrome are traditionally treated with prednisone 2 mg/kg/day or 60 mg/m2/day. Retrospective data support the use of lower doses. We designed a prospective randomized pilot study to investigate the efficacy of different doses in achieving remission of steroid sensitive nephrotic syndrome relapse. The cohort included 30 children with relapsed steroid sensitive nephrotic syndrome, mean age 6.3 ± 3 years and mean disease duration 2.2 ± 1.8 years. The children were randomized to receive 2, 1.5, or 1 mg/kg/day prednisone. The corresponding times to response, defined as the first of 3 consecutive days without proteinuria, were 7.2 ± 1.4, 10.2 ± 5.1, and 9 ± 3.3 days; the difference between the 1.5 and 2 mg/kg/day groups was statistically significant. One patient each in the 1 mg/kg/day and the 1.5 mg/kg/day groups failed to respond and were switched to 2 mg/kg/day, leading to a response after 3 and 10 days, respectively. Mean cumulative prednisone doses in the 3 groups were 45.5 ± 3.4, 42.7 ± 25.9, and 24.9 ± 7.4 mg/kg, respectively (P < 0.05).
Conclusion: In the present study, treatment of childhood steroid sensitive nephrotic syndrome relapse with prednisone 1-1.5 mg/kg/day led to a significantly lower cumulative dose than the standard dose. Treatment with a lower dose may be equally safe and effective to the standard dose.What is Known:• Relapses of steroid-sensitive nephrotic syndrome are traditionally treated with standard-dose steroids.• Treatment with corticosteroids may have significant adverse effects mainly with long-term use.What is New:• Treatment of steroid sensitive nephrotic syndrome relapse with 1-1.5 mg/kg/day prednisone may lead to a significantly lower cumulative dose.• Treatment with a lower steroid dose may be as effective as the standard dose in achieving remission of steroid sensitive nephrotic syndrome relapse.

Entities:  

Keywords:  Low dose; Prednisone; Steroid treatment; Steroid-sensitive nephrotic syndrome

Mesh:

Substances:

Year:  2019        PMID: 31728673     DOI: 10.1007/s00431-019-03506-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.

Authors:  Vaishnavi Raman; Sriram Krishnamurthy; K T Harichandrakumar
Journal:  Pediatr Nephrol       Date:  2016-01-12       Impact factor: 3.714

2.  Dosing of glucocorticosteroids in nephrotic syndrome.

Authors:  Otto Mehls; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2011-09-09       Impact factor: 3.714

Review 3.  Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.

Authors:  Rebecca M Lombel; Debbie S Gipson; Elisabeth M Hodson
Journal:  Pediatr Nephrol       Date:  2012-10-03       Impact factor: 3.714

Review 4.  Side effects of corticosteroid therapy.

Authors:  A L Buchman
Journal:  J Clin Gastroenterol       Date:  2001-10       Impact factor: 3.062

5.  Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries.

Authors:  Georges Deschênes; Marina Vivarelli; Licia Peruzzi
Journal:  Eur J Pediatr       Date:  2017-03-16       Impact factor: 3.183

6.  Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children.

Authors:  Karnika Raja; Ami Parikh; Hazel Webb; Daljit Hothi
Journal:  Pediatr Nephrol       Date:  2016-09-27       Impact factor: 3.714

Review 7.  Nephrotic syndrome in childhood.

Authors:  Allison A Eddy; Jordan M Symons
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

8.  Management of childhood onset nephrotic syndrome.

Authors:  Debbie S Gipson; Susan F Massengill; Lynne Yao; Shashi Nagaraj; William E Smoyer; John D Mahan; Delbert Wigfall; Paul Miles; Leslie Powell; Jen-Jar Lin; Howard Trachtman; Larry A Greenbaum
Journal:  Pediatrics       Date:  2009-07-27       Impact factor: 7.124

9.  Substantial practice variation exists in the management of childhood nephrotic syndrome.

Authors:  Susan Samuel; Catherine J Morgan; Martin Bitzan; Cherry Mammen; Allison B Dart; Braden J Manns; R Todd Alexander; Robin L Erickson; Silviu Grisaru; Andrew W Wade; Tom Blydt-Hansen; Janusz Feber; Steven Arora; Christoph Licht; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2013-08-06       Impact factor: 3.714

10.  Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality.

Authors:  Andrea Pasini; Gabriella Aceto; Anita Ammenti; Gianluigi Ardissino; Vitalba Azzolina; Alberto Bettinelli; Elena Cama; Sante Cantatore; Antonella Crisafi; Giovanni Conti; Maria D'Agostino; Alessandra Dozza; Alberto Edefonti; Carmelo Fede; Elena Groppali; Chiara Gualeni; Alessandra Lavacchini; Marta Lepore; Silvio Maringhini; Paola Mariotti; Marco Materassi; Francesca Mencarelli; Giovanni Messina; Amata Negri; Marina Piepoli; Fiammetta Ravaglia; Angela Simoni; Laura Spagnoletta; Giovanni Montini
Journal:  Pediatr Nephrol       Date:  2014-08-17       Impact factor: 3.714

View more
  6 in total

Review 1.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Susan M Samuel; Narelle S Willis; Jonathan C Craig; Elisabeth M Hobson
Journal:  Cochrane Database Syst Rev       Date:  2020-08-31

2.  [Clinical assessment of moderate-dose glucocorticoid in the treatment of recurrence of primary nephrotic syndrome in children: a prospective randomized controlled trial].

Authors:  Juan Tu; Chao-Ying Chen; Hai-Yun Geng; Hua-Rong Li; Hua Xia; Yuan Lin; Tian-Tian Lin; Jin-Shan Sun
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-05-15

Review 3.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.

Authors:  Agnes Trautmann; Olivia Boyer; Elisabeth Hodson; Arvind Bagga; Debbie S Gipson; Susan Samuel; Jack Wetzels; Khalid Alhasan; Sushmita Banerjee; Rajendra Bhimma; Melvin Bonilla-Felix; Francisco Cano; Martin Christian; Deirdre Hahn; Hee Gyung Kang; Koichi Nakanishi; Hesham Safouh; Howard Trachtman; Hong Xu; Wendy Cook; Marina Vivarelli; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2022-10-21       Impact factor: 3.651

4.  Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis.

Authors:  Anne M Schijvens; Nynke Teeninga; Eiske M Dorresteijn; Steven Teerenstra; Nicholas J Webb; Michiel F Schreuder
Journal:  Eur J Pediatr       Date:  2021-03-28       Impact factor: 3.183

5.  Comparison and Analysis of Gut Microbiota in Children With IgA Vasculitis With Different Clinical Symptoms.

Authors:  Meng Li; Xiaoming Wang; Xingjie Lin; Xiuju Bian; Rui Jing; Andrew Frelinger; Aijun Zhang
Journal:  Front Pediatr       Date:  2022-01-07       Impact factor: 3.418

Review 6.  Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome.

Authors:  Martin T Christian; Andrew P Maxted
Journal:  Pediatr Nephrol       Date:  2021-02-20       Impact factor: 3.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.